{"entity":{"id":"paula-ghaneh","kind":"person","name":"Paula Ghaneh","aka":[],"tldr":"Liverpool pancreatic surgeon, chief investigator of ESPAC5, the UK trial of short-course neoadjuvant treatment for borderline resectable pancreatic cancer, and a co-author of ESPAC-3 and ESPAC-4.","summary":"Paula Ghaneh is Professor of Surgery in the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool (Institute of Systems, Molecular and Integrative Biology). She was first author of ESPAC5 (Lancet Gastroenterology and Hepatology 2023), the four-arm phase 2 trial that compared immediate surgery with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX or chemoradiotherapy in borderline resectable pancreatic cancer, and a co-author of ESPAC-3 (JAMA 2010) and ESPAC-4 (Lancet 2017), the Liverpool-led adjuvant trials whose result, gemcitabine plus capecitabine after resection, is NICE NG85's adjuvant recommendation.","asOf":"2026-09-24","links":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/paula-ghaneh"}],"tags":["pancreatic","trialist","uk","surgeon"],"related":["daniel-palmer","chris-halloran"],"cancers":["pancreatic","borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine","capecitabine","folfirinox"],"companies":[],"institutions":["liverpool-hpb-centre"],"pathways":[],"terms":[],"trials":["espac-3","espac-4","espac-5"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Surgery, Molecular and Clinical Cancer Medicine, University of Liverpool","institutionId":"liverpool-hpb-centre","specialisms":["Pancreatic surgery","Adjuvant and neoadjuvant trials","Surgical oncology"],"profiles":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/paula-ghaneh"}],"papers":[{"title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)","journal":"Lancet Gastroenterology and Hepatology","year":2023,"doi":"10.1016/S2468-1253(22)00348-X"},{"title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(16)32409-6"},{"title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection (ESPAC-3)","journal":"JAMA","year":2010,"doi":"10.1001/jama.2010.1275"}]},"route":"/people/paula-ghaneh/","neighbours":{"person":[{"id":"andrew-biankin","kind":"person","name":"Andrew Biankin","route":"/people/andrew-biankin/"},{"id":"chris-halloran","kind":"person","name":"Chris Halloran","route":"/people/chris-halloran/"},{"id":"daniel-palmer","kind":"person","name":"Daniel Palmer","route":"/people/daniel-palmer/"}],"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"institution":[{"id":"liverpool-hpb-centre","kind":"institution","name":"Liverpool University Hospitals HPB centre (Aintree)","route":"/institutions/liverpool-hpb-centre/"}],"trial":[{"id":"espac-3","kind":"trial","name":"ESPAC-3","route":"/trials/espac-3/"},{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/"},{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/"}]}}